Pharmacologic Management for Heart Failure and Emerging Therapies.

Diana H Kim, Feng-Ju Chien, Howard J Eisen

Journal: Current cardiology reports 2017;19(10):94

PMID: 28840572

Abstract

PURPOSE OF REVIEW

This review aims to summarize the growing body of literature of HF with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) with a focus on recent pharmacologics.

RECENT FINDINGS

HFrEF continues to be more widely investigated than HFpEF. Ivabradine and combinatorial treatment with sacubitril and valsartan are promising newly approved therapies. Other experimental therapies have emerged, which include Serelaxin, Empagliflozin, Neuregulin, and Omecamtive mecarbil, among others. These drugs need to continue to be investigated for safety and efficacy. We predict ivabradine and combinatorial treatment with sacubitril-valsartan to develop as a widespread therapy. New therapies should be aimed at treating HFpEF or target the cardiomyocyte itself.

Address: Drexel University College of Medicine, 2900 W Queen Lane, Philadelphia, PA, 19129, USA. [email protected].; Drexel University College of Medicine, 2900 W. Queen Lane, Philadelphia, PA, 19145, USA. [email protected].; Villanova University, 800 Lancaster Ave, Villanova, PA, 19085, USA.; Drexel University College of Medicine, 2900 W Queen Lane, Philadelphia, PA, 19129, USA.

DOI: 10.1007/s11886-017-0899-x

Link outs

Free resources

Medical:

https://medlineplus.gov/heartfailure.html

Other Literature Sources:

Miscellaneous:

https://assays.cancer.gov/non-CPTAC-2658

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-GZMA-1

Subscription / membership required

Full Text Sources:

https://dx.doi.org/10.1007/s11886-017-0899-x

MeSH Terms: Aminobutyrates, Benzazepines, Benzhydryl Compounds, Biphenyl Compounds, Cardiovascular Agents, Drug Combinations, Glucosides, Heart Failure, Humans, Ivabradine, Neuregulin-1, Recombinant Proteins, Relaxin, Stroke Volume, Tetrazoles, Urea, Valsartan